Novo Nordisk: Yet Another Negative Surprise
Pharmaceutical companies bear the risk that trials may fail to deliver suitable results at the last minute, thereby rendering years of investment worthless. That is exactly what is happening to Novo Nordisk right now. The Danish company suffered a major setback with the latest trial data on ziltivekimab and lost a whopping EUR 25 billion in market value within hours. In a regulatory Phase III trial, the drug failed to meet the primary endpoint for reducing serious cardiovascular events such as heart attacks or strokes, dealing a significant blow to hopes for a multi-billion growth driver outside the GLP-1 business.
Analysts at Jeffries described the result as “strategically negative,” as ziltivekimab was seen as a potential pillar in the lucrative cardiovascular market and could have reduced the company’s reliance on Ozempic and Wegovy. Nevertheless, Novo Nordisk remains exceptionally well-positioned operationally, as the two blockbusters continue to rank among the world’s most successful drugs for diabetes and obesity, while the company is pushing ahead with the launch of tablet versions and further indication expansions. At the same time, the company is engaged in intense competition with Eli Lilly for dominance in the booming GLP-1 market, which is raising the pressure to innovate to a new level. While the recent trial setback is weighing on sentiment in the short term, it does not change the fact that Novo Nordisk, with its strong market position and a well-stocked development pipeline, remains one of the leading growth stocks in the pharmaceutical industry over the long term. Only 10 out of 32 analysts on the LSEG platform gave it a thumbs-up and expect an average price of DKR 326 or EUR 43.50. Just under 8% above yesterday’s close!
Pfizer: Strong Dividend Meets a Well-Stocked Drug Pipeline
Things are going better at Pfizer. The US pharmaceutical giant once again reported robust financial results in Q2 2026, largely meeting market expectations. This performance was driven primarily by the strong oncology division and the growing portfolio of innovative drugs, while dependence on previous COVID-related revenue continues to decline. At the same time, the pharmaceutical company is working intensively on its pipeline and recently announced, among other things, an FDA Priority Review for the TALZENNA + XTANDI combination, as well as further regulatory progress for IBRANCE, PADCEV, and several oncology projects. The long-term growth strategy is thus increasingly driven by new therapies in the areas of cancer, rare diseases, and immunology. With a 12-month performance of nearly 14%, Pfizer ranks among the sector’s top performers. The stock remains particularly attractive for income-oriented investors, as the quarterly dividend has once again been set at USD 0.43 per share, which corresponds to an attractive dividend yield of around 7% based on the current share price. With 351 consecutive quarterly dividends to date, the company impressively underscores its shareholder-friendly business policy.
Vidac Pharma: From Biotech Hidden Gem to Potential Pharmaceutical Partner of the Future
Vidac Pharma is part of a new generation of biotechnology companies that do not fight cancer with increasingly potent drugs, but rather aim to specifically disrupt the metabolism of tumour cells. At the heart of this approach is the enzyme hexokinase-2 (HK2), which gives many cancer cells their extraordinary ability to survive and is considered the hub of the so-called Warburg effect. With its lead candidate, VDA-1102, the company aims to break through this protective mechanism, disrupt the energy supply to tumour cells, and simultaneously reactivate programmed cell death.
If this approach succeeds, it could result in a platform technology that can be applied to numerous tumour types and address an oncology market worth more than USD 200 billion. Vidac reached an important operational milestone in June with the successful completion of patient enrollment for all 39 participants in the ongoing Phase 2b trial for high-risk actinic keratosis. Now that the planned follow-up period has ended, investors are focusing on the first topline data, which are considered the next major value driver. The company is also gaining momentum from the continuous expansion of its patent portfolio, which was recently strengthened by another patent grant in Canada and further improves the technology’s international protection.
At the same time, Vidac is working on its strategic expansion into continental Europe and aims to establish a presence in the renowned biotechnology network Quest for Health in Strasbourg, which has mobilized more than EUR 220 million in financing for its member companies over the past three years. This significantly improves access to scientific collaborations, specialized investors, and potential pharmaceutical partners. In contrast to Pfizer, which relies on a broad portfolio of already established drugs and marketing structures worth billions, Vidac Pharma focuses entirely on developing a novel metabolic platform—one that carries correspondingly higher risk but also offers significantly greater potential for value appreciation. Sphene Capital sees 36-month price targets of over EUR 4, though this could rise significantly further if the company succeeds.
Gerresheimer: Analysts Are Not Entirely Positive
Gerresheimer’s stock was pushed down to EUR 14.80 in the first quarter. But that came to an end last week! In a veritable fireworks display, the price surged from around EUR 26 to over EUR 32. The reason: the packaging and pharmaceutical specialist has taken a decisive step forward by selling off several business units. For approximately EUR 1.5 billion, the company is divesting its US subsidiary Centor and its global plastic primary packaging business to Apax Partners, thereby gaining significant leverage to reduce debt. Although Gerresheimer will lose approximately EUR 570 million in revenue, more than a quarter of its previous business volume, it will regain financial stability and strategic focus in return. Going forward, the group will focus more strongly on higher-margin growth areas such as drug delivery systems, pre-filled syringes, specialty glass solutions for biopharma applications, and medical components. Presumably, the recent high short interest of 7.68% prompted some short sellers to cover their positions, as the outlook has improved significantly. Following balance sheet issues, downward revisions to forecasts, and a loss of confidence, Gerresheimer now has the opportunity to emerge from the crisis stronger and reposition itself as a focused partner to the global pharmaceutical and biotech industries. Many research firms have adjusted their ratings. JPMorgan is at “Overweight” with a price target of EUR 46, Jefferies remains at “Hold” with a target of EUR 26.80, and UBS has even issued a “Sell” rating with a price target of EUR 12.90. On the LSEG platform, the median stands at EUR 33.70—a solid 20% above the current price of EUR 27.80. It will be interesting to see how the story unfolds, as the stock has come down from EUR 120 during the peak of the COVID-19 pandemic.
A roller coaster ride on the markets? Perfect—it is precisely in this wild up-and-down action that positive surprises lurk! While Gerresheimer is already charging full steam ahead toward a major comeback, even the most seasoned pros at Novo Nordisk are still wondering whether the turnaround is finally getting on track. Pfizer, on the other hand, caught its skeptics completely off guard with stellar quarterly results, leaving the bears with long faces. And at Vidac Pharma? A lot is going on behind the scenes, so the next news release is sure to be a major event.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a “Transaction”). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
